Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial.
Annals of the rheumatic diseases（2022）
摘要
NCT02955615.
更多查看译文
关键词
autoimmunity,biological therapy,lupus erythematosus, systemic
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要